COVID-19 mRNA vaccines: Platforms and current developments

Gábor Tamás Szabó,1,2 Azita Josefine Mahiny,1,2 and Irena Vlatkovic1

1BioNTech SE, An der Goldgrube 12, Mainz 55131, Germany
2These authors contributed equally

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in a preclinical study nearly 30 years ago, numerous advances have been made in the field of mRNA therapeutic technologies. This research uncovered the unique favorable characteristics of mRNA vaccines, including their ability to give rise to non-toxic, potent immune responses and the potential to design and upscale them rapidly, making them excellent vaccine candidates during the coronavirus disease 2019 (COVID-19) pandemic. Indeed, the first two vaccines against COVID-19 to receive accelerated regulatory authorization were nucleoside-modified mRNA vaccines, which showed more than 90% protective efficacy against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection alongside tolerable safety profiles in the pivotal phase III clinical trials. Real-world evidence following the deployment of global vaccination campaigns utilizing mRNA vaccines has bolstered clinical trial evidence and further illustrated that this technology can be used safely and effectively to combat COVID-19. This unprecedented success also emphasized the broader potential of this new drug class, not only for other infectious diseases, but also for other indications, such as cancer and inherited diseases. This review presents a brief history and the current status of development of four mRNA vaccine platforms, nucleoside-modified and unmodified mRNA, circular RNA, and self-amplifying RNA, as well as an overview of the recent progress and status of COVID-19 mRNA vaccines. We also discuss the current and anticipated challenges of these technologies, which may be important for future research endeavors and clinical applications.

INTRODUCTION

Vaccines are important tools to prevent, control, and/or eradicate infectious diseases and are fundamental components of public health programs worldwide.1 The development and approval of effective coronavirus disease 2019 (COVID-19) vaccines represented a significant milestone during the ongoing pandemic. A vast number of parallel vaccine development projects were launched to combat the disease caused by a previously unknown pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of January 14, 2022, there were 333 vaccine candidates in development, of which 139 have entered the clinical phase according to the World Health Organization’s vaccine tracker.2

Rapid development and highly efficient immune responses brought messenger ribonucleic acid (mRNA) technologies to the forefront of the COVID-19 vaccine race, mainly due to the fact that the technology requires a sequenced viral genome rather than live virus and takes merely a couple of days to design.3 Furthermore, the upscaling of cell-free vaccine production is relatively straightforward, thereby providing a cutting-edge tool for rapid response in epidemics and pandemics.4–7 Of the COVID-19 vaccines that have entered clinical trials as of this writing, 23 (17%) are mRNA-based candidates.7 Moreover, the first two vaccines to receive conditional marketing authorization (CMA) from the European Medicines Agency or emergency use authorization (EUA) from the US Food and Drug Administration (FDA) were nucleoside-modified mRNA vaccines from BioNTech/Pfizer and Moderna, respectively, and showed over 90% protective efficacy against symptomatic SARS-CoV-2 infection in their phase III clinical trials,8,9 surpassing previous expectations.10

In this review, we summarize the preclinical and clinical data of the vaccine candidates, which fall under four mRNA vaccine platforms: non-replicating linear nucleoside-modified and unmodified mRNA, circular RNA (circRNA), and self-amplifying RNA (saRNA). In addition, we discuss potential challenges that may hinder future vaccine development programs.

THE PATH TO COVID-19 mRNA VACCINE DEVELOPMENT

Compared with traditional vaccines, which are relatively slow and laborious to develop,1,11,12 mRNA-based vaccines have features that allow them to be rapidly designed and upscaled while still being highly potent and low cost.10 Although mRNA vaccines were already being investigated in clinical trials for other diseases, e.g., cancer, their far-reaching potential was not realized until the COVID-19 pandemic, where mRNA vaccine candidates were some of the first to enter clinical trials and obtain accelerated regulatory approvals.13,14 Without the extensive research and technological advances over the past three decades, this achievement would not have been possible. This section highlights some of the most important breakthroughs that ultimately

https://doi.org/10.1016/j.ymthe.2022.02.016.

Correspondence: Gábor Tamás Szabó, BioNTech SE, An der Goldgrube 12, Mainz 55131, Germany.
E-mail: gabor.szabo@biontech.de
carved the way to COVID-19 mRNA vaccine development and approval.

Following the discovery of mRNA, research in this area surged and gave rise to multiple scientific breakthroughs ultimately leading to the development of RNA-based vaccines. Examination of the properties of mRNA was previously hampered by the minimal cellular uptake of naked mRNA. However, the development of protective lipid-based formulations, which were first successfully used in 1978 in a study where rabbit reticulocyte 9S mRNA was introduced into mouse lymphocytes, resulting in globin synthesis, made subsequent mRNA research pursuits less complex. In the same year, protein expression was also induced in human cells after liposomal mRNA transport. Later, the efficacy of transfection was further enhanced with the incorporation of a synthetic cationic lipid into liposomes for mRNA delivery.

The identification of deoxyribonucleic acid (DNA)-dependent RNA polymerase enzymes was a crucial step leading to in vitro mRNA transfection (IVT) using DNA templates. First published in 1984, IVT made the transcription of a selected functional mRNA from a template in the desired quantity possible. It was not until 1993 that mRNA was used as a vaccine for the first time to elicit a specific immune response against the encoded pathogenic antigen in a preclinical setting using lipid-based delivery. Another 20 years later, mRNA vaccines against infectious disease were investigated in phase I, proof-of-concept, clinical trials.

Based on the potential toxicity of liposomes in clinical application, the success of the first approved small interfering RNA-lipid nanoparticle (LNP) therapeutic and mRNA COVID-19 vaccines originates only from their delivery using ionizable lipid-containing LNPs, which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection or in muscle cells after intramuscular (i.m.) injection. Moreover, it was recently found that LNPs possess a potent adjuvant function, which further demonstrates their beneficial effects in vaccine application.

Lack of mRNA stability and innate immune activation were important concerns for many years in the development of mRNA as a drug substance. Uridine-containing mRNA stimulates the innate immune response and has an established pathogenic antigen in a preclinical setting using lipid-based delivery. Another approach to reducing dose levels is the use of an mRNA platform that is able to self-amplify.

In addition to linear mRNA, other mRNA vaccine platforms have received attention. circRNA was first identified in 1976 and was later detected in human cells. Although it was initially thought not to serve as a translational template, later reports contradicted this hypothesis, triggering further research. Given its enhanced bio-stability compared with linear RNA due to the lack of terminals preventing degradation, circRNA could be a promising research avenue. Another approach to reducing dose levels is the use of an mRNA platform that is able to self-amplify.

Subsequent viral biology research led to the insertion of an RNA-dependent RNA polymerase (RdRp) sequence next to the antigen-encoding sequence, leading to the amplification of the antigen of interest in the cytoplasm. Along with the intracellular RNA replication of the antigen of interest, saRNA can lead to high antigen production at a low dose.

THE MECHANISM OF IMMUNIZATION WITH mRNA VACCINES AND SELECTION OF THE SARS-CoV-2 ANTIGEN

Immunization with mRNA vaccines requires an antigen-encoding mRNA transcript formulated into LNPs that is delivered to antigen-presenting cells (APCs) (Figure 1). LNP-mRNA is endocytosed and released through the process of endosomal escape to the cytoplasm, where the antigen of interest is produced and presented as a membrane-bound antigen by transfected cells, including muscle cells and APCs, resulting in activation of B cells, CD4+ helper T cells, and CD8+ cytotoxic T cell responses (Figure 1). The germinal center B cell response and its regulation by CD4+ T follicular helper (Tfh) cells are of key importance for high-affinity neutralization antibody titers and long-lasting B cell responses. Tfh cells recognize antigens on the APC surface and help to activate B cells, which in turn produce high-affinity virus-neutralizing antibodies. Recently, it was found that the LNP component of LNP-mRNA vaccines has adjuvant activity, which is dependent on its ionizable lipid component and IL-6 from the compromise between LNP adjuvant function and modified mRNA, allowing improved efficacy and safety. Despite the multiple advantages offered by the mRNA-LNP platform, there is still room for improvement, and we will likely see further iterations of this technology.
cytokine induction. LNP-driven adjuvant activity leads to induction of strong Th1 cell responses and humoral immunity, thus enhancing the efficacy of mRNA-based vaccines. This LNP-driven adjuvant activity helps activate CD8+ cytotoxic T cells that may specifically recognize and eliminate virus-infected cells (Figure 1). Indeed, a persistent antigen-specific germinal center B cell response and plasmablast response in blood and draining lymph nodes are elicited after vaccination with SARS-CoV-2 LNP-mRNA in humans, leading to the development of a robust and prolonged humoral immunity.

The entire surface spike (S) glycoprotein of SARS-CoV-2 or the receptor binding domain (RBD) of the S protein, which is critical for viral entry into the host cell, represent the most widely selected and suitable antigen target sites in COVID-19 vaccine development. Both the full-length S protein and the RBD itself are immunogenic and induce a strong protective neutralizing antibody response after recognition by the immune system. Immune responses are improved by introducing two consecutive proline residues (2P), which are known to retain the full-length S protein in the prefusion conformation. The S protein is cleaved by the host cell protease furin into subunits (S1 and S2), which support cellular entry. Interestingly, the C-terminal motif of the cleaved S1 subunit can bind to neuropilin-1 (NRP-1), which negatively influences T cell memory. Consequently, a loss-of-function modification or deletion of the furin cleavage site of the S protein in vaccine development can be beneficial.

The efficacy of a viral antigen-encoding mRNA vaccine is influenced by codon optimization of the coding sequence, but not just in relation to stability and translatability. A recent study revealed that cryptic epitopes, originating from out-of-frame open reading frames during SARS-CoV-2 infection, can be modified or lost during codon optimization, leading to either enhanced or diminished immunogenic responses.

**NUCLEOSIDE-MODIFIED mRNA VACCINES**

Numerous vaccine candidates were being investigated in the early stages of the COVID-19 pandemic, including nucleoside-modified LNP-mRNA vaccines, which were the first to enter clinical trials and receive EUAs, CMAs, and later full regulatory approvals. At present, there are a total of eight nucleoside-modified LNP-mRNA vaccine candidates in clinical trials, all of which share the key feature of enabling the replacement of all uridines in the mRNA with 1-methylpseudouridine (m1Ψ) (Table 1).

mRNA and LNP features of nucleoside-modified vaccines have been extensively summarized elsewhere. Here, we highlight the main disclosed differences in the characteristics of the mRNA constructs (Figure 2). BioNTech/Pfizer’s modRNA platform RNA sequence (used for BNT162b2) consists of human α-globin 5′ untranslated region (UTR), amino-terminal enhancer of split (AES), and m1tRNA 3′ UTR motifs and a poly(A) tail consisting of A30LA70 (linker [L]: GCAUAUGACU), while the mRNA...
Table 1. Nucleoside-modified COVID-19 LNP-mRNA vaccines in clinical trials

| Name | Developer | Clinical phase, trial identifier | Dose, regimen | Antigen coding sequence | Formulation | Clinical outcome | Regulatory authority approval date |
|------|-----------|---------------------------------|---------------|--------------------------|-------------|-----------------|---------------------------------|
| BNT162b2 | BioNTech/Pfizer | phase I/II/III (IV), and phase III booster dose NCT04368728 | 30 µg (10, 20, 30 µg tested in phase I); p-b in 3 weeks | full-length S prefusion-stabilized; optimized, GC-rich | Acuitas LNP | 95% protection against symptomatic COVID-19 in participants 16 years or older and 100% efficacy in participants 12 to 15 years of age<sup>8</sup> | EUA by FDA, December 11, 2020; CMA by EMA, December 21, 2020; Full approval by FDA, August 23, 2021 |
| | | phase II booster dose, NCT05004181, NCT04955626 | 30 µg (booster dose); p-b in 3 weeks | | | | EUA by FDA for those ≥ 12 years of age, May 10, 2021; under CMA, by EMA, May 28, 2021 |
| | | phase II/III, NCT04816643 | 10 µg dose for 5- to 11-year-olds; p-b in 3 weeks | | | 90.7% efficacy in participants 5 to 11 years of age<sup>9</sup> | EUA by FDA for 5- to 11-year-olds, October 29, 2021; under CMA, by EMA, November 25, 2021 |
| | BioNTech/Pfizer | phase I/II/III, NCT04368728 | 10, 20, 30, 100 µg tested in phase I; p-b in 3 weeks | RBD, secreted | Acuitas LNP | positive clinical data, BNT162b1 was selected for a pivotal efficacy study based on favorable safety data<sup>10,11</sup> | EUA by FDA, December 18, 2020; CMA by EMA, January 6, 2021 |
| | BioNTech/Fosun | phase I, NCT04523571 | RBD trans-membrane | Moderna LNP | 94.1% efficacy at preventing COVID-19 illness, including severe disease in participants 18 years or older and 95% efficacy in 12- to 17-year olds<sup>12</sup> | EUA by FDA, January 31, 2022<sup>33</sup> | full approval by FDA, January 31, 2022<sup>33</sup> |
| mRNA-1273 | Moderna/ NIAID/BARDA | phase III (IV) NCT04811664, phase III, NCT04470427 | 100 µg (25, 100, 250 µg tested in phase I); p-b in 4 weeks | full-length S prefusion-stabilized | Moderna LNP | | single booster dose under EUA, by FDA, October 20, 2021; under CMA, by EMA, October 25, 2021 |

(Continued on next page)
| Name            | Developer              | Clinical phase, trial identifier | Dose, regimen        | Antigen coding sequence | Formulation | Clinical outcome                                      | Regulatory authority approval date |
|-----------------|------------------------|----------------------------------|----------------------|-------------------------|-------------|-------------------------------------------------------|----------------------------------|
| mRNA-1273.211   | Moderna                | phase II/III, NCT04927065        | 50, 100 μg; booster  | full-length S prefusion-stabilized | Moderna LNP | boosters increased neutralization titers against key variants<sup>45</sup> |                                   |
| mRNA-1273.351   | Moderna                | phase II, NCT04405076            | 20, 50 μg; booster   | full-length S prefusion-stabilized against B.1.351 | Moderna LNP | not published                                         |                                   |
| TAK-919         | Takeda/Moderna         | phase I/II, NCT04677660          | N/A μg; p-b in 4 weeks | full-length S prefusion-stabilized | Moderna LNP | not published                                         | PMDA, Japan, May 21, 2021        |
| ChulaCov19      | Chulalongkorn University | phase II, NCT04566276          | 10, 25, 50 μg; p-b in 3 weeks | full-length S           | Genevant LNP | not published                                         |                                   |

EMA, European Medicines Agency; EUA, emergency use authorization; CMA, conditional marketing authorization; FDA, US Food and Drug Administration; GC, guanine-cytosine; LNP, lipid nanoparticle; p-b, prime-boost regimen; PMDA, Pharmaceuticals and Medical Devices Agency; S, spike protein; RBD, receptor binding domain.
Figure 2. Widely used mRNA-based COVID-19 vaccines: Comparison of ingredients

BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) are composed of 1-methylpseudouridine-modified full-length spike mRNA, with proline substitutions, that is GC rich, codon optimized, and composed of standard mRNA components: cap, 5’ UTR, coding sequence, 3’ UTR, and a poly(A) tail. BNT162b2 is co-transcriptionally capped with ((m27,3’-O)Gppp(m2’-O)ApG) cap1 and has human α-globin 5’ UTR, AES, and mRNAR1 3’ UTR motifs; two stop codons; and a poly(A) tail consisting of A30L-A70. mRNA-1273 is enzymatically capped and has an undisclosed 5’ UTR and a human β-globin gene-based 3’ UTR, three stop codons, and a poly(A) tail of undisclosed length. In both cases, the mRNA is formulated using LNPs consisting of ionizable, structural, and stealth lipids and cholesterol. The LNPs of both mRNA vaccines contain DSPC and cholesterol. Unique features of BNT162b2 and mRNA-1273 LNP formulations are the use of ALC-0315 and SM-102 ionizable lipids and ALC-0159 and PEG2000-DMG, PEG-based stealth lipids, respectively. Lipids are integrated into the LNPs under specific molar ratios.

In addition to the mRNA and LNP components, the only ingredients are salts (PBS and Tris buffers for BNT162b2 and mRNA-1273, respectively) and 10% sucrose that is used as a cryoprotectant for both mRNA vaccines. ALC-0159, which consist of four components: ionizable lipids, structural lipids, stealth lipids, and cholesterol.

sequences developed by Moderna (mRNA-1273, mRNA-1273.211, mRNA-1273.351), Takeda (TAK-919), and Chulalongkorn University (ChulaGov19) are not fully disclosed. Capping of BNT162b2 was performed co-transcriptionally using a trinucleotide cap1 analog ((m27,3’-O)Gppp(m2’-O)ApG) (TriLink), while Moderna used enzymatic capping to obtain cap1 for their preclinical mRNA-1273. All eight nucleoside-modified mRNAs are formulated using one of three types of LNP originating from Acuitas, Moderna, and Genevant, which consist of four components: ionizable lipids, structural lipids, stealth lipids, and cholesterol.

The design and preclinical testing of nucleoside-modified mRNA vaccines is based on years of research; thus, at the start of the COVID-19 pandemic they were well placed for rapid adjustments and application to SARS-CoV-2. However, one of the bottlenecks that required significant innovation was manufacturing, process development, and scale-up methods to meet supply demands for large-scale clinical trials and later worldwide marketing. The details of the manufacturing processes are proprietary to the companies producing nucleoside-modified mRNA vaccines and not disclosed in literature.

Figure 3 outlines the basic steps of this manufacturing and scale-up: IVT, mRNA purification, formulation process, and downstream steps up to fill and finish. One of the key steps in this process is mRNA purification, which allows depletion of double-stranded RNA (dsRNA) contaminants. Through recognition of TLR3 in endosomes or retinoic acid-inducible gene I, melanoma differentiation-associated protein 5, and inflammasomes in the cytoplasm, depending on the amount, dsRNAs might overactivate innate immunity and lead to adverse events. The exact purification processes performed for BNT162b2 and mRNA-1273 used on a large manufacturing scale are undisclosed. HPLC is a gold standard for mRNA purification in a lab setting; however, it presents challenges when scaling up, and thus it can only be speculated that certain adjustments had to be made between the mRNA vaccine purity and the manufacturing process that allows the scale necessary to produce enough vaccine to meet global requirements during a pandemic. Another possibility is innovation on the IVT level (e.g., by using engineered RNA polymerases and specific reaction conditions) that could lead to a significant decrease in dsRNA formation during the IVT reaction, allowing achievement of excellent purity with standard industry purification methods. A thermostable RNA polymerase has been recently used for mRNA IVT and to prevent formation of dsRNA, allowing a lower immune response to such mRNA without the purification step. In 2021, Moderna provided details on their T7 RNA polymerase, which is able to minimize dsRNA formation; however, its potential use in mRNA-1273 vaccine production is currently not publicly disclosed and can only be speculated.

The dosing of nucleoside-modified LNP-mRNAs against COVID-19 applied in clinical trials ranged between 10 and 250 μg RNA (Table 1). BNT162b2 was granted EUA by the FDA on December 11, 2020, for a 30 μg dose for individuals 16 years or older for the prevention of COVID-19, and the EUA for mRNA-1273 was granted shortly after on December 18, 2020, for individuals 18 years of age and older at a dose of 100 μg. Full approval by the FDA was granted for BNT162b2 for individuals 16 years and older and mRNA-1273 for...
individuals 18 years and older on August 23, 2021, and on January 31, 2022, respectively. All nucleoside-modified LNP-mRNAs referred to in Table 1 are administered i.m. in a prime-boost (p-b) regimen with a 3 week interval for BNT162b2 and ChulaCov19, or a 4 week interval for mRNA-1273 and TAK-919.

In preclinical studies, one i.m. injection of BNT162b1 or BNT162b2 was sufficient to elicit an inhibitory antibody response with high titers as well as CD4+ helper and CD8+ cytotoxic T cell responses. Two injections of BNT162b2 administered to rhesus macaques elicited SARS-CoV-2 neutralizing antibody titers 8.2- to 18.2-fold higher than in convalescent human sera. The safety and immunogenicity data of the phase I/II trials of BNT162b1 and BNT162b2 supported the selection of BNT162b2 for a phase II/III trial based on milder systemic reactions and strong adaptive humoral and poly-specific cellular immune responses against epitopes conserved in diverse SARS-CoV-2 virus variants. In the BNT162b2 phase II/III trial, with a total of 43,548 participants 16 years of age or older, two doses of BNT162b2 resulted in confirmation of the favorable safety profile and 95% vaccine efficacy (prevention of COVID-19). In 12- to 15-year-olds, two 30 μg doses of BNT162b2 showed a favorable safety profile and resulted in 100% vaccine efficacy. Recently, as a part of the clinical trial examining BNT162b2 in 5- to 11-year-olds (NCT04816643), two 10 μg doses of BNT162b2 were found to give rise to 90.7% vaccine efficacy (prevention of COVID-19). Owing to the reduced efficacy of LNP-mRNA vaccines over time and the emergence of highly transmissible SARS-CoV-2 variants such as delta (B.1.617.2) and omicron (B.1.529), the effects of booster vaccination are being examined. An Israeli study looking at the population ≥60 years of age receiving a single booster of BNT162b2 given at least 5 months after completion of the p-b primary regimen demonstrated 95% fewer reports of severe illness and significantly lower rate of confirmed COVID-19 cases.

Recently, multiple trials have investigated vaccine-induced immunity against the delta (B.1.617.2) and omicron (B.1.1.529) variants. In all cases, neutralizing antibody titers after the second dose of mRNA-based vaccines were highly reduced for omicron (B.1.1.529) compared with delta (B.1.617.2) and especially compared with the wild-type variant, while the third dose significantly improved antibody neutralization titers. This suggests that application of a booster dose of mRNA vaccines may protect against these highly transmissible variants and supports booster vaccine doses, which are now being rolled out globally. A booster dose of BNT162b2 obtained EUA by the FDA on September 22, 2021, for individuals ≥65 years of age or ≥18 years at high risk of severe COVID-19. Currently, clinical trials with authorized vaccines in specific population groups, including 6-month- to 4-year-old children, pregnant women, immunocompromised individuals, and cancer patients, are ongoing (Table 2).

mRNA-1273 went through a clinical development process similar to that of BNT162b2, and a favorable safety profile and 94.1% vaccine efficacy (protection in preventing COVID-19 illness, including severe disease) for those ≥18 years of age was demonstrated in a pivotal clinical phase II/III trial. In an interim analysis
of a single booster dose following p-b vaccination, Moderna tested mRNA-1273 and multiple variant-modified versions and found high safety and tolerability, as well as increased neutralization titers against key variants of concern and variants of interest of SARS-CoV-2, including beta (B.1.351), gamma (P.1), delta (B.1.617.2), and omicron (B.1.1.529).86 In 12- to 17-year-olds, mRNA-1273 showed 95% vaccine efficacy and had an acceptable safety profile.84 A single booster dose of mRNA-1273 obtained EUA by the FDA on October 20, 2021, while numerous clinical trials for specific population groups are currently recruiting (Table 2).

While initial clinical trials included healthy volunteers, an important aspect is the safety and efficacy in pregnant women, who were not included. A recent observational study in a cohort of 10,861 pregnant women showed that BNT162b2 had 96% effectiveness in the prevention of COVID-19.115 In a smaller patient cohort with 131 individuals, BNT162b2 and mRNA-1273 were studied in pregnant or lactating women, and both vaccines led to robust humoral immunity with no significant differences in postvaccination reactogenicity between pregnant and non-pregnant women.116 Importantly, functional neutralizing antibodies against SARS-CoV-2 were found in infant cord blood and in the breast milk of vaccinated pregnant women, suggesting that there is a protective effect for newborns.116–118 In January 2022, the European Medicine Agency’s COVID-19 task force finalized a detailed review of multiple studies in pregnant woman, including about 65,000 pregnancies. Based on the results, the use of mRNA-based COVID-19 vaccines during pregnancy is encouraged, since no increased risk of pregnancy complications for expectant mothers and their unborn babies was found, and effectiveness was not compromised compared with non-pregnant women.119

### Table 2. Clinical development of BioNTech/Pfizer and Moderna COVID-19 vaccines in specific population groups

| Name | Sponsor of clinical trial | Clinical phase, identifier | Population type | Population | Age | Estimated primary completion date |
|------|---------------------------|----------------------------|-----------------|------------|-----|-----------------------------------|
| BioNTech SE | phase II/III, NCT04816643 | healthy | healthy individuals | 6 months to 18 years | June 18, 2024 |
| BioNTech SE | phase III, NCT04754594 | healthy | pregnant women | ≥ 18 years | October 15, 2022 |
| BioNTech SE | phase II, NCT04895982 | immunocompromised | immunocompromised | ≥ 12 years | February 11, 2023 |
| Centre Hospitalier Régional d’Orléans | phase IV, NCT04952766 | immunocompromised | kidney transplant, myeloma, cancer, hematologic malignancy, multiple sclerosis, hypergammaglobulinemia, malignant tumors, HIV, diabetes mellitus type 2 | ≥ 18 years | March 2022 |
| BNT162b2 | University of Liège | phase III, NCT04951323 | immunocompromised | allogeneic stem cell recipients | 18 to 100 years | December 1, 2021 |
| | Humanity & Health Medical Group Ltd. | phase IV, NCT04775069 | immunocompromised | chronic liver cell disease | ≥ 18 years | December 31, 2021 |
| | National Institute of Allergy and Infectious Diseases (NIAID) | phase II, NCT04761822 | immunocompromised | high-allergy/mast cell disorder | ≥ 12 years | October 2021 |
| | Assistance Publique-Hôpitaux de Paris | Phase II/III, NCT04969601 | cancer | acute leukemia | ≥ 12 years | April 2022 |
| Moderna | phase III, NCT04470427 | healthy | healthy individuals | ≥ 18 years | October 27, 2022 |
| Moderna | phase III, NCT04649151 | healthy | healthy individuals | 12 to 17 years | June 30, 2022 |
| | phase III, NCT04796896 | healthy | healthy individuals | 6 months to 11 years | June 12, 2023 |
| Moderna | phase III, NCT04860297 | immunocompromised | solid organ transplant recipients | ≥ 18 years | March 31, 2023 |
| mRNA-1273 | McGill University Health Centre/Research Institute of the McGill University Health Centre | phase III, NCT04806113 | immunocompromised | rheumatic diseases, rheumatoid arthritis, systemic lupus erythematosus | ≥ 18 years | June 13, 2021 |
| NIAID | phase II, NCT04761822 | immunocompromised | high-allergy/mast cell disorder | ≥ 12 years | October 2021 |
| National Cancer Institute (NCI) | phase II, NCT04847050 | cancer | solid tumor malignancies, hematologic malignancies, lymphoma, multiple myeloma | ≥ 18 years | January 1, 2022 |

HIV, human immunodeficiency virus.
UNMODIFIED mRNA VACCINES

The optimization of mRNA constructs, including the coding sequence, can regulate immunogenicity without incorporation of modified nucleosides. Uridine depletion to reduce counterproductive immune reactions can be achieved by the replacement of uridine by codon optimization, but this must be balanced with regard to transfer RNA abundance. Currently, there are no marketed unmodified mRNA vaccines, but candidates are being investigated in clinical trials (Table 3).

Table 3. Unmodified mRNA COVID-19 vaccine candidates being tested in clinical trials

| Name             | Developer                      | Clinical phase, trial identifier | Dose, regimen | Antigen coding sequence | Formulation       | Clinical outcome                                                                 |
|------------------|--------------------------------|---------------------------------|---------------|-------------------------|-------------------|----------------------------------------------------------------------------------|
| CVnCoV           | CureVac                        | phase Ib/III, NCT04652102        | 12 µg, p-b, 4 weeks | full-length S, 2P       | Acuitas LNP       | 48% efficacy for the prevention of COVID-19 in age group 18–80 years.122         |
|                  |                                | phase I, II, NCT04449276,        |               |                         |                   |                                                                                  |
|                  |                                | NCT04515147                     |               |                         |                   |                                                                                  |
| MRT5500 (VAV00001) | Translate Bio/Sanofi            | phase I/II, NCT04798027          | 7.5 µg, p-b, 3 weeks | full-length S 2P,     | LNP                | not published                                                                    |
|                  |                                |                                 |               | modified furin cleavage site |                   |                                                                                  |
| ARCoV            | AMS/Walvax/Suzhou               | phase II, ChCTR2100041855        | 15 µg, p-b, 2 to 4 weeks | RBD                    | LNP                | well tolerated in seronegative 18- to 64-year-old individuals, strong IgG antibody response.34 |
|                  |                                | phase III, NCT04847102           |               |                         |                   |                                                                                  |
| PTX-COVID19B     | Providence Therapeutics         | phase I (II), NCT04765436        | 16, 40, 100 µg, p-b, 4 weeks; 40 µg was selected for phase II | full-length S       | LNP                | neutralizing activity without any safety concerns in both age groups (20–64 and 65–74 years).123 |
|                  |                                |                                 |               |                         |                   |                                                                                  |
|                  |                                | phase II, NCT05175742 comparison with BNT162b2 | 60, 80 µg, p-b, 4 weeks |                         | not published       |                                                                                  |
| DSS670           | Daiichi Sankyo                 | phase I/II, NCT04821674          | dose not disclosed, p-b | not disclosed           | LNP                |                                                                                  |
| SW-0123          | Stemirna Therapeutics/          | phase I, ChCTR2100045984         | 10, 30, 60, 100 µg, p-b | full-length S          | LPP                | not published                                                                    |
|                  | Shanghai East Hospital          |                                 |               |                         |                   |                                                                                  |
| EG-COVID         | eyeGENE                        | phase I/IIa                      | 50, 100, 200 µg, p-b, 3 weeks | full-length S         | cationic liposome   | not published                                                                    |

**2P**, two consecutive proline residues; AMS, Academy of Military Science of the Chinese People’s Liberation Army; IgG, immunoglobulin G; LNP, lipid nanoparticle; LPP, core-shell structured lipopolyplex; p-b, prime-boost regimen; RBD, receptor binding domain; S, spike protein.

The favorable safety profile of the CVnCoV vaccine candidate using the RNAActive mRNA vaccine platform developed by CureVac was confirmed at up to a 12 µg dose, but later in the phase Ib/III trial, using a p-b regimen with 12 µg 4 weeks apart, only 48% efficacy was disclosed for the prevention of COVID-19 at any severity in all age groups among 39,680 participants, which finally led to its withdrawal from the regulatory approval process. The inherent limitations of unmodified mRNA vaccines against COVID-19 are yet to be overcome. These limitations are based on the intrinsic immunogenicity of unmodified mRNA due to intracellular detection and type I interferon (IFN) production, which in turn is responsible for the inhibition of translation, the reduction of CD8+ T cell activation, and the inhibition of T helper cell generation. These alterations possibly lead to a blunted specific immune response. However, CureVac further engineered the UTRs of the mRNA and showed a superior immunological profile in preclinical tests, and subsequently, in collaboration with GlaxoSmithKline, CureVac plans to investigate this second-generation candidate in a clinical program. MRT5500, developed by Translate Bio and Sanofi, was examined in a phase I/II trial where different doses (15, 45, or 135 µg) were administered with a 3 week interval without safety or tolerability concerns. Interestingly, the MRT5500 vaccine candidate was designed using the full-length S protein with a loss-of-function modified furin cleavage site (RRAR682-685GSAS)-encoding sequence. However, the developers decided not to proceed with a phase III clinical trial for the vaccine candidate. BioNTech/Pfizer started COVID-19 vaccine development in three different mRNA vaccine platforms, including one utilizing unmodified mRNA. BNT162a2, a full-length S protein encoding unmodified linear mRNA, was not selected for later-stage clinical trials. The ArCoV vaccine candidate, developed through the cooperation of Walvax Biotechnology, Suzhou Abogen Biosciences, and the Academy of Military Science of the Chinese People’s Liberation Army, is registered for entering late-stage clinical assessment. The investigational product is an RBD-encoding, LNP-mRNA, which is administered as a 15 µg dose in a p-b regimen. The developers emphasize thermostability, as their vaccine can be stored at room temperature for at least 1 week, which was confirmed in preclinical studies.
Therapeutics, entered a phase II clinical trial following preclinical testing and a successful phase I trial, which showed that it had a tolerable safety profile at a dose of up to 100 μg among seronegative individuals, and induced high neutralizing antibody levels. In January 2022, a clinical trial was started to compare PTX-COVID19-B with individuals, and induced high neutralizing antibody levels. In January to S protein, resulting in the production of virus-like particles, Jiao Tong University is developing three candidates, including one according to preclinical study results. EyeGene developed a prefusion-stabilized form, and is formulated into a core-shell structure. The mRNA encodes the natural full-length S protein rather than a prefusion-stabilized form, and is formulated into a core-shell structure lipopolypylex (LPP), making it highly selective to dendritic cells, according to preclinical study results. EyeGene developed a proprietary formulation using cationic liposome to avoid the use of polyethylene glycol and to facilitate freeze-drying during production. Their candidate is scheduled to enter testing in a phase I/IIa trial in Korea in late 2021.

Furthermore, numerous development projects in preclinical phases aim to create an effective COVID-19 vaccine using an unmodified linear mRNA platform, including the Max Planck Institute of Colloids and Interfaces (Germany), Selçuk University (Turkey), CanSino (China) in collaboration with Precision NanoSystems, BIOCAD (Russia), RNImmune (USA), Greenlight Biosciences (USA), IDIBAPS (Spain), Cell Tech Pharmed (Iran), ReNAP (Iran), and Globe Biotech Ltd. (Bangladesh). In particular, a unique formulation developed by eTheRNA makes their candidate suitable for intranasal administration, which could prove advantageous in vaccination against SARS-CoV-2 by activation of mucosal immunity. A consortium of RNA Cure BioPharma, Fudan University, and Shanghai Jiao Tong University is developing three candidates, including one that encodes membrane (M) and envelope (N) proteins in addition to S protein, resulting in the production of virus-like particles, marking a different approach with regard to the chosen antigen and in contrast to other mRNA vaccine candidates.

**circRNA VACCINES**

circRNA (also called endless RNA) can be translated in eukaryotic cells and, due to its closed-ring structure, is significantly more resistant to exonuclease-mediated degradation compared with linear mRNA. Despite these potential benefits, there is only one circRNA COVID-19 vaccine candidate under development, which is produced using a group 1 ribozyme autocatalysis strategy but, as of January 31, 2022, has not yet entered clinical trials. The RBD antigen-encoding sequence of this circRNA, which is encapsulated in LNP s, was fused with signal peptide sequences to ensure secretion of antigens and to improve binding capacity. To drive translation, an undisclosed internal ribosome entry site (IRES) was positioned in front of the antigen-encoding sequence. In the preclinical study, the candidate was administered to mice i.m. at two different doses (10 and 50 μg) in a p-b regimen 2 weeks apart, which elicited a high titer of neutralizing antibodies in a dose-dependent manner, with Th1-biased T cell responses.

**saRNA VACCINES**

Similar to other mRNA vaccine platforms, saRNA facilitates rapid candidate design and development, as well as cell-free molecule synthesis. Moreover, owing to its self-replicative nature, in which the encoded replica enables multiple copies of the antigen-encoding RNA, lower doses seem to be required to reach the same translational level compared with non-replicative mRNAs. saRNA vaccines are inherently self-adjuvants, as their replica activity leads to dsRNA and replicon intermediates during transcription mimic a viral infection. This triggers a broader immune response, which was also considered to have potential to be effective with a single-dose inoculation.

Several clinical trials investigating the safety and efficacy of saRNA vaccines against COVID-19 are currently ongoing (Table 4). The front-running and disclosed candidates are designed with Venezuelan equine encephalitis virus (VVEV)-derived replica in one RNA molecule with the antigen coding sequence predominantly full-length S protein. Most of the clinical trials are using p-b immunization or comparing a single dose with a p-b regimen. Only one candidate, EXG5003, is undergoing testing with only a single-dose administration. One of the main obstacles concerning the platform is the large size of the saRNA, as it contains the non-structural protein encoding sequence derived from the alphavirus genome necessary for replicative activity. The length of the RNA substantially influences the stability and ease of delivery. However, there is no saRNA COVID-19 vaccine candidate that was developed using the previously successfully applied size reduction method.

After a preclinical in vivo experiment demonstrating proof of principle for an effective saRNA candidate against COVID-19, Imperial College London entered LNP-sCoVsaRNA into a phase I/II clinical trial. Doses of 0.1–10 μg showed a dose-dependent immune response; however, there was no seroconversion in a significant portion of the trial participants, all of whom were seronegative at inclusion for SARS-CoV-2 infection and, accordingly, the clinical development process was halted. The self-adjuvant effect of saRNA is partly related to the activation of types I and III IFN, which has the potential to induce a negative feedback loop and inhibit translation. Accordingly, despite lower doses, the use of saRNA vaccines lead to higher reactogenicity.

To avoid this, a candidate with an undisclosed redesigned saRNA backbone to dampen IFN production is being studied in the phase I CO-VAC-Uganda trial (LNP-sCoV saRNA-02), which assesses immune response in SARS-CoV-2 antibody seronegative and seropositive individuals, but is not directly testing efficacy against COVID-19. One of the first saRNA vaccine candidates to enter the clinical phase, BNT162c2, was developed and tested by BioNTech; however, this vaccine format was not selected for further clinical investigation. Arcturus
Therapeutics, in collaboration with Duke-NUS Medical School, is studying three candidates (ARCT-021, ARCT-154, ARCT-165) using their STARR mRNA saRNA platform. The company’s first candidate, ARCT-021, was tested in a phase I/II trial with a single-dose regimen and p-b dosing in the range of 1–10 μg. Currently, a single-dose regimen is being investigated in an ongoing phase II trial. ARCT-154 has started a phase I/II/III trial in Vietnam using a modified antigen-encoding sequence focusing on the recent alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617.2) virus variants. Addressing the question of the boost application of saRNA, all three candidates will be directly compared in a phase II/III trial in previously vaccinated and unvaccinated individuals in the United States and in Singapore. First results have been released from 24 participants, in which a 5 μg booster dose of ARCT-154 or ARCT-165 5 months after immunization with BNT162b2 resulted in a robust increase in neutralizing antibody responses against the omicron variant (B.1.1.529) after booster injection.164

All saRNA candidates that are being tested in the clinic were designed for i.m. administration, with the exception of EXG-5003 (Elixirgen Therapeutics), which is formulated for intradermal administration, rendering it effective only at the injection site in a temperature-sensitive manner.165 In an extensive collaboration of SENAI Cimatec, Gennova Biopharmaceuticals, HDT Biotech, and Quratis, another candidate, HDT301 (also called repRNA-CoV2S or HGCO19), is being tested in a phase I/II trial. In the preclinical setting, the p-b regimen has been shown to induce a more potent T cell response in comparison with the administration of a single dose;166 however, in the ongoing clinical trial, a one-shot regimen is also being tested. Data from a phase I trial in India demonstrated that Gennova’s COVID-19 RNA vaccine candidate HGCO19 has an acceptable safety and tolerability profile.167

Recently, another important question has emerged regarding the boost potential of different vaccine modalities, specifically, the heterologous administration of two different products. In the preclinical setting, a heterologous vaccine regimen of an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) followed by saRNA was tested, which resulted in improved antigen-specific antibody responses and a higher neutralization effect compared with the p-b homologous vaccine regimen.168 Similarly, Gritstone Bio has an saRNA vaccine candidate (SAM-SARS-CoV-2), which is being investigated in a phase I clinical trial among individuals previously immunized with an adenoviral-vector vaccine169. SAM-SARS-CoV-2 is designed to elicit immune responses against S and the nucleoprotein, as well as the membrane protein and open reading frame 3, which may bolster its efficacy against variants of concern.170

There are several other vaccine candidates on the horizon that will enter clinical trials in the immediate future, such those developed by Ziphius Vaccines with Ghent University and by Amyris (USA) in collaboration with the Infectious Disease Research Institute, which has promising preclinical data justifying a clinical development program.171

| Name                        | Developer                                      | Clinical phase, trial identifier | Dose, regimen | Antigen coding sequence | LNP features | Clinical outcome                          |
|-----------------------------|-----------------------------------------------|---------------------------------|---------------|--------------------------|--------------|------------------------------------------|
| LNP-nCoVsaRNA               | Imperial College London                       | phase I/II, ISRCTN17072692      | 0.1 to 10 μg, p-b, 4 weeks | full-length S, prefusion-stabilized | LNP          | dose-dependent immunological effect up to 5 μg, seroconversion 8%–61% by ELISA, 46%–87% by immunoblot assay169 |
| LNP-nCOV saRNA-02           | Imperial College London/MRC/UVRI/LSHTM/Uganda Research Unit | phase I, NCT04934111           | 5 μg, p-b, 4 weeks | full-length S, prefusion-stabilized | LNP          | not published                            |
| EXG5003                     | Elixirgen Therapeutics                         | phase I/II, NCT04863131         | N/A μg, one dose | RBD                      | LNP          | not published                            |
| ARCT 021                    | Arcturus Therapeutics/Duke-NUS Medical School  | phase II/III, NCT05012943       | 0.2 to 10 μg ARCT 021: 5 μg, one dose or p-b, 4 weeks | full-length S, prefusion-stabilized | LUNAR        | dose-dependent binding and neutralizing antibody responses in interim data160 |
| ARCT 154                    | Arcturus Therapeutics/Duke-NUS Medical School  | phase II, NCT04840957          | 1, 5, 25 μg, one dose or p-b in 4 or 8 weeks | full-length S | LNP          | not published                            |
| ARCT 165                    | Arcturus Therapeutics/Duke-NUS Medical School  | phase I/II, NCT0507097          | 10 μg, one dose as booster | full-length S, perfusion stabilized, mutated furin cleavage site | LNP          | not published                            |
| HDT301 (repRNA-CoV2S, HGCO19) | SENAI Cimatec/HDT'/Gennova/Quratis         | phase I, NCT04844268           | 1, 5, 25 μg, one dose or p-b in 4 or 8 weeks | full-length S | N/A          | N/A                                      |
| VLPICOV-01                  | VLP Therapeutics Japan                        | phase I, jRCT2071210067        | N/A           | N/A                      | N/A          | not published                            |
| SAM-SARS-CoV-2              | Gritstone                                     | phase I                         | 10 μg, one dose as booster | full-length S, perfusion stabilized, mutated furin cleavage site | LNP          | not published                            |

GSK, GlaxoSmithKline; LION, Lipid inorganic nanoparticles; LNP, lipid nanoparticle; LSHTM, London School of Hygiene and Tropical Medicine; LUNAR, lipid-enabled nucleic acid delivery reagent; MRC, Medical Research Council; N/A, not applicable/not disclosed; p-b, prime-boost regimen; RBD, receptor binding domain; S, spike protein; UVRI, Uganda Virus Research Institute.
CONCLUSION AND OUTLOOK

The COVID-19 pandemic led to the fastest vaccine development in history. \(^{172}\) Although the therapeutic potential of mRNA had previously been investigated for many decades without being available as a marketed medical treatment, the time was now ripe to harness its unique features compared with conventional vaccine approaches. In this review, we aimed to give an overview of the approved COVID-19 mRNA vaccines and vaccine candidates as well as their different molecular biology approaches in this fast-moving field.

If a suitable antigen sequence is available to target, mRNA vaccine technology facilitates rapid design and production because it does not involve pathogens or growing the vaccine by specific cell culture processes or fermentation. In contrast, these challenges make traditional vaccine research, development, and production processes more complex and lengthy. \(^{173}\)

The two vaccines against COVID-19 to first gain accelerated approvals and meet the required safety and efficacy standards were mRNA vaccines. \(^8,81,62\) Nucleoside-modified mRNA in LNPs seems to be the superior choice over unmodified candidates, as demonstrated by the clinical efficacy and safety data. While relatively similar dose levels of unmodified mRNA and saRNA vaccine candidates were tested in phase I trials, unmodified mRNA vaccines that proceeded to later stages of clinical testing were used at lower doses compared with nucleoside-modified mRNA vaccines. Since none of the unmodified mRNA and saRNA candidates have made it to an approval stage as of this writing, it may be speculated that this is due to intrinsic adverse effects caused by the unmodified nucleosides or immunostimulatory by-products. circRNA represents a favorable concept, but it seems that further improvement is necessary prior to continuing their development as drug candidates. The circRNA platform is theoretically compatible with the replacement of uridine; however, to our knowledge, the functionality of an IRES element in combination with modified nucleosides is yet to be demonstrated.

The flexibility of LNP–mRNA-based vaccine design and scalability of manufacturing, in contrast to conventional technologies, may allow for a rapid response to other novel SARS-CoV-2 variants in the case where the efficacy of the vaccine designed for the original strain is lower. Nowadays, different approaches are in the pipeline with the use of mRNA platforms that aim to have a variant-specific response, including modified, adjusted coding sequences for new strains or heterologous vaccine administration. In January 2022, BioNTech and Pfizer announced that a new clinical trial has started to test an omicron (B.1.1.529)-specific mRNA vaccine in healthy adults. \(^{174}\) Similarly, Moderna started a phase II study to test their omicron-specific booster candidate (mRNA-1273.529). \(^{175}\)

The success of mRNA vaccines in the COVID-19 vaccine race emphasized the promising potential of this technology in a wide variety of future applications, \(^4,176,177\) including other infectious diseases, \(^4\) cancer therapy, \(^178,179\) and protein replacement therapies, \(^180,181\) which is reflected in the current pipelines of the developers.

However, it must be considered that, in addition to the success of the first mRNA vaccines, the proof of a versatile future usage of this technology must be delivered. Profound immunogenicity data for therapeutic usage in non-inflammatory environments is still missing. It is also expected that the world will have to deal more frequently with new pandemics, and, in terms of COVID-19, novel virus variants of concern may arise and manifest in the population. Here, the mRNA technology could prove its suggested supremacy regarding speed of design and scale-up and cost efficiency when adapting to new sequences or even other diseases. Israel, a country with extensive real-world data on COVID-19 vaccine effectiveness due to its rapid vaccine rollout, reported a drop in neutralizing antibody titer to less than 10% of the initial titer after vaccination. \(^182\) This raises concerns regarding additional booster doses of the highly similar mRNA vaccine and if it may cause host tolerance, which is particularly pertinent if the vaccine needs to be administered several times a year or seasonally. Although immune escape of the omicron (B.1.1.529) variant has been reported, \(^183\) data from Israel have shown that there is a significantly lower rate of SARS-CoV-2 infection after a booster-immunization compared with after the primary two-dose series. \(^184\) Ultimately, the world will need multiple adaptable vaccine technologies in parallel to cover supply demands. In terms of mRNA vaccine use for other diseases, the fundamentals of a therapeutic mRNA vaccine for the induction of antigen-specific tolerization in the treatment of experimental autoimmune encephalomyelitis, a mouse model for multiple sclerosis, have been developed. \(^185\) Some of the future applications of mRNA technology include individualized cancer vaccines, \(^186,187\) co-stimulatory ligand receptors, cytokines, immunomodulators, and mRNA-encoded antibodies, as well as chimeric antigen receptors (CARs), and are extensively reviewed elsewhere. \(^179\) Despite the current hype of mRNA technology, many researchers are already pursuing novel methods to improve mRNA composition and expansion into their fields of application.

The administration routes of mRNA therapies are mainly limited to i.m. and i.v.; however, there are encouraging results addressing different modes of delivery. It seems beneficial to reach the respiratory tract epithelium in airborne diseases in order to prime lung-resident memory T cells. \(^188\) In addition to different indications, \(^189,190\) a COVID-19 vaccine candidate for intranasal delivery is being investigated. \(^191\) For enteral use, an interesting approach is the milli-injector capsule with nanoparticle formulations of nucleic acids, which is able to deliver to the gastric epithelia. \(^191\) Furthermore, norovirus and SARS-CoV-2 sequences have been combined to generate an orally delivered saRNA vaccine. \(^192\) Recombinant murine cytomegalovirus was successfully used in mice as a vector-based vaccine against influenza and SARS-CoV-2. \(^193\) Others pursue DNA-based vaccine approaches to fight drug resistance in cancer. \(^194\) Adenoviral-based drug delivery is an option to deliver nucleic acids (reviewed by Sakurai et al. \(^195\)); however, repeated administration could fail to induce
or greatly reduce the desired immune response due to induction of anti-adenoviral antibodies by the host.\textsuperscript{196}

The new mRNA vaccines must still overcome several challenges to meet the world market needs. The further development of an adjustable formulation platform resulting in even lower or no adverse effects is crucial, especially in terms of choice of lipids and their charge and biodegradability. Hurdles for continuous production could be the availability and scalability of essential reagents. Furthermore, low-income countries should have equitable access to these new vaccines, which will be instrumental in tackling the pandemic. BioNTech and Pfizer have designed a three-step price system depending on the income level of a country, of which the lowest price is a non-profit price, financed by the higher price for high-income countries, such as the United States or the European Union.\textsuperscript{197} Similarly, Moderna states that they are “aiming to provide effective and affordable vaccines and therapeutics to all populations.”\textsuperscript{198}

In summary, mRNA-based therapeutics have key advantages in terms of their versatility and adaptability, which could lead to promising therapies not only for infectious diseases but for other indications such as cancer, and thus, further research and investment into this technology is warranted. Given the success of the technology thus far, the expectations are high and so could be the reward.

Source of the data
References published as of January 31, 2022, about mRNA vaccine candidates were selected from the PubMed online library and from publications without finalized peer review available on the medRxiv and bioRxiv preprint servers. In addition, announcements, communications, and press releases from pharmaceutical companies and health care agencies were cited to enable a timely review. Relevant information about ongoing clinical trials was identified using ClinicalTrials.gov and the Chinese Clinical Trial Registry websites.

ACKNOWLEDGMENTS
We would like to express our special thanks to Andrew Finlayson, PhD, and Camilla West, PhD, of BioNTech SE for scientific and medical writing support. We owe special thanks to Katalin Karikó for her advice and discussion of literature choice.

DECLARATION OF INTERESTS
G.T.S., A.J.M., and I.V. are all full-time employees at BioNTech SE, Mainz, Germany, and may hold shares from BioNTech SE.

REFERENCES
1. Pollard, A.J., and Bijker, E.M. (2021). A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100. https://doi.org/10.1038/s41577-020-00479-7.
2. WHO. Vaccine tracker: vaccines as of 14th January. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
3. Corbett, K.S., Edwards, D.K., Leist, S.R., Abiona, O.M., Boyoglu-Barnum, S., Gillespie, R.A., Himansu, S., Schäfer, A., Ziwayo, C.T., DiPiazza, A.T., et al. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567–571. https://doi.org/10.1038/s41586-020-2622-0.
4. Alameh, M.-G., Weissman, D., and Pardi, N. (2020). Messenger RNA-based vaccines against infectious diseases. Curr. Top. Microbiol. Immunol. https://doi.org/10.1007/82_2020_202.
5. Pardi, N., Hogan, M.J., Porter, F.W., and Weissman, D. (2018). mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279. https://doi.org/10.1038/nrd.2017.243.
6. Pardi, N., Hogan, M.J., and Weissman, D. (2020). Recent advances in mRNA vaccine technology. Curr. Opin. Immunol. 65, 14–20. https://doi.org/10.1016/j.coi.2020.01.008.
7. Pardi, N., and Weissman, D. (2017). Nucleoside-modified mRNA vaccines for infectious diseases. Methods Mol. Biol. 1499, 109–121. https://doi.org/10.1007/978-1-4939-6681-9_6.
8. Polsack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615. https://doi.org/10.1056/NEJMoa2034577.
9. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphadel, N., Creech, C.B., et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416. https://doi.org/10.1056/NEJMoa2035389.
10. WHO. WHO target product profiles for COVID-19 vaccines, Updated April 9, 2020, https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines.
11. Pronker, E.S., Weenen, T.C., Commandeur, H., Claassen, E.H.J.M., and Osterhaus, A.D.M.E. (2013). Risk in vaccine research and development quantified. PLoS One 8, e57755. https://doi.org/10.1371/journal.pone.0057755.
12. Plotkin, S. (2014). History of vaccination. Proc. Natl. Acad. Sci. U S A 111, 12283–12287. https://doi.org/10.1073/pnas.1400472111.
13. EMA. EMA recommends first COVID-19 vaccine for authorisation in the EU, Updated December 21, 2020, https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu.
14. FDA. FDA approves first COVID-19 vaccine, Updated August 23, 2021, https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.
15. Brenner, S., Jacob, F., and Meselson, M. (1961). An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature 190, 576–581. https://doi.org/10.1038/190576a0.
16. Gros, F., Hiatt, H., Gilbert, W., Kurland, C.G., Risebrough, R.W., and Watson, J.D. (1961). Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli. Nature 190, 581–585. https://doi.org/10.1038/190581a0.
17. Dimitriadi, G.J. (1978). Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes. Nature 274, 923–924. https://doi.org/10.1038/274923a0.
18. Ostro, M.J., Giacomoni, D., Lavelle, D., Paxton, W., and Dray, S. (1978). Evidence for translation of rabbit globin mRNA after liposome-mediated insertion into a human cell line. Nature 274, 921–923. https://doi.org/10.1038/274923a0.
19. Malone, R.W., Felgner, P.L., and Verma, I.M. (1989). Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. U S A 86, 6077–6081. https://doi.org/10.1073/pnas.86.16.6077.
20. Melton, D.A., Krieg, P.A., Rebagliati, M.R., Maniatis, T., Zinn, K., and Green, M.R. (1984). Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 12, 7035–7056. https://doi.org/10.1093/nar/12.18.7035.
21. Krieg, P.A., and Melton, D.A. (1984). Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs. Nucleic Acids Res. 12, 7057–7070. https://doi.org/10.1093/nar/12.18.7057.
22. Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillot, J.G., Lévy, J.P., and Meulien, P. (1993). Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719–1722. https://doi.org/10.1002/eji.1830230749.
23. Alberer, M., Gnad-Vogt, U., Hong, H.S., Mehr, K.T., Backert, L., Finak, G., Gottardo, R., Bica, M.A., Garofano, A., Koch, S.D., et al. (2017). Safety and immunogenicity of
infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. Preprint at medRxiv. https://doi.org/10.1101/2021.04.05.21254592.

125. Daichii. Development progress of mRNA COVID19 vaccine in Japan: press release, Updated October 21, 2021, https://www.daichisankyo.com/files/news/pressrelease/pdf/2021/20211021_E.pdf.

126. Rauch, S., Gooch, K., Hall, Y., Salguero, F.J., Dennis, M.J., Gleeson, F.V., Harris, D., Ho, C., Humphries, H.E., Longet, S., et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. https://doi.org/10.1101/2020.12.23.241438.

127. Rauch, S., Roth, N., Schwendt, K., Fotin-Mleczek, M., Mueller, S.O., and Petsch, B. (2021). mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPI Vaccines 6, 57. https://doi.org/10.1080/25723347.2021.1939852.

128. Rauch, S., Lutz, J., Kowalczyk, A., Schläke, T., and Heidenreich, R. (2017). RNAActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol. Biol. 1499, 89–107. https://doi.org/10.1007/978-1-4939-6841-9_5.

129. Kremsner, P.G., Mann, P., Kroidl, A., Leroux-Roels, I., Schindler, C., Gabor, J.J., Schunk, M., Leroux-Roels, G., Bosch, J.J., Fendel, R., et al. (2021). Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: a phase 1 randomized clinical trial. Wien. Klin. Wochenschr. 133, 931–941. https://doi.org/10.1007/s00508-021-01922-y.

130. Kremsner, P., Guererro, R.A.A., Arana, E., Martinez, G.J.A., Bonten, M.J.M., Chandler, R., Corral, G., De Block, E.J.J., Ecker, L., Gabor, J.J., et al. Efficacy and safety of the mRNA SARS-CoV-2 mRNA vaccine candidate: results from Herald, a phase 2b/3, randomised, observer-blinded, placebo-controlled clinical trial in ten countries in Europe and Latin America: Herald study preprint data. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3911826.

131. Chen, N., Xia, P., Li, S., Zhang, T., Wang, T.T., and Zhu, J. (2017). RNA sensors of sensing by pattern recognition receptors. J. Innate Immun.

132. Beuckelaer, A.D., Pollard, C., van Lint, S., Roose, K., van Hoecke, L., Naessens, T., Zhan, Y., et al. (2021). A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct. Target. Ther. 6, 213. https://doi.org/10.1186/s41392-021-00634-z.

133. Liu, J., Budylovsky, P., Samson, R., Griffin, B.D., Babadzadeh, G., Rathod, B., Colwill, K., Abioye, J.A., Schwartz, J.A., Law, R., et al. (2022). Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COV19-D. Sci. Adv. 8, eaby9815. https://doi.org/10.1126/sciadvaby9815.

134. NCT0175742. PTX-COV19-B, an mRNA humoral vaccine, intended for prevention of COVID-19 in a general population. This study is designed to demonstrate the safety, tolerability, and immunogenicity of PTX-COV19-B in comparison to the Pfizer-BioNTech COVID-19 vaccine. Updated January 4, 2022, https://clinicaltrials.gov/ct2/show/NCT0175742.

135. Yang, R., Deng, Y., Huang, B., Huang, L., Lin, A., Li, Y., Wang, W., Liu, J., Lu, S., Zhan, Y., et al. (2021). A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduct. Target. Ther. 6, 213. https://doi.org/10.1186/s41392-021-00634-z.

136. Korea Biomedical Review. Eye gene wins approval for trial of mRNA Covid-19 vaccine, Updated September 1, 2021, https://www.koreabiomed.com/news/articleView.html?idno=12040.

137. Contract Pharma. Trillink extends EyeGene partnership for COVID-19 vaccine development: CleanCap technology to be used in the production of EG-COVID mRNA COVID-19 vaccine for clinical trials, Updated October 5, 2021, https://www.contractpharma.com/contents/view_breaking_news/2021-10-05/trillink-extends-eye-gene-partnership-for-covid-19-vaccine-development/.

138. Nag, K., Chandra Baray, J., Rahman Khan, M., Mahmud, A., Islam, J., Myti, S., Ali, R., Haq Sarker, E., Kumar, S., Hossain Chowdhury, M., et al. (2021). An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immune response with single dose. Vaccine 39, 3735–3755. https://doi.org/10.1016/j.vaccine.2021.05.035.

139. eTheRNA Press Release. eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations, Updated Marcicus 24, 2020, https://epivax.com/news/press-release-etherna-consortium-cov-2-mrna-vaccine-for-high-risk-populations.

140. Lu, J., Lu, G., Tan, S., Xia, J., Xiong, H., Yu, X., Qi, Q., Yu, X., Li, L., Yu, H., et al. (2020). A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 30, 936–939. https://doi.org/10.1101/2021.06.30.122511.

141. Li, H., Liu, J., Guo, D., Li, X., Pan, Z., Gao, S., Wang, J., et al. (2021). Preclinical evaluation of a self-amplifying RNA vaccine: implications of virus-neutralising antibodies and mediates protection in rodents. J. Virol. 95, e00204–20.

142. Kjems, J. (2019). The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 673–691. https://doi.org/10.1038/s41576-019-01558-7.

143. Bloom, K., van den Berg, F., and Arbutnath, P. (2021). Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 28, 117–129. https://doi.org/10.1038/s41343-020-00204-y.

144. Pepini, T., Pulchino, A.M., Cariello, T., Carlson, A.L., Sari-Sarraf, F., Ramsauer, K., Debusatis, J.C., Maruggi, G., Otten, G.R., Grall, A.J., et al. (2017). Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198, 4012–4024. https://doi.org/10.4049/jimmunol.1601877.

145. Maruggi, G., Zhang, C., Li, J., Ulmer, J.B., and Yu, D. (2019). mRNA as a transformati“e technology for vaccine development to control infectious diseases. Mol. Ther. 27, 757–772. https://doi.org/10.1016/j.ymthe.2019.01.020.

146. Jensen, S., and Thomsen, A.R. (2012). Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J. Virol. 86, 2900–2910. https://doi.org/10.1128/JVI.05738-11.
156. Vogel, A.B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K.C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018). Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26, 446–455. https://doi.org/10.1016/j.ymthe.2017.11.017.

157. Blakney, A.K., McKay, P.F., and Shattock, R.J. (2018). Structural components for amplification of positive and negative strand VEEV splitzicons. Front. Mol. Biosci. 5, 71. https://doi.org/10.3389/fmolb.2018.00071.

158. Beissert, T., Perkovic, M., Vogel, A., Erbar, S., Walzer, K.C., Hempel, T., Brüll, S., Haefner, E., Becker, R., Türeci, O., et al. (2020). A trans- amplifying RNA vaccine strategy for induction of potent protective immunity. Mol. Ther. 28, 119–128. https://doi.org/10.1016/j.ymthe.2019.09.009.

159. Pollock, K.M., Cheeseman, H.M., Srebotj, A.I., Libri, V., Boffito, M., Owen, D., Bern, H., O’Harra, J., McFarlane, I.R., Lemm, N.-M., et al. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial: COVAC1 human phase I study. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3859294.

160. BioPharma Dealmakers. Arcturus—a clinical-stage mRNA therapeutics and vaccines company: clinical results. https://www.nature.com/articles/d44374-021-00073-3.

161. McKay, P.F., Hu, K., Blakney, A.K., Samannu, K., Brown, J.C., Penn, R., Zhou, J., Bouton, C.R., Rogers, P., Polra, K., et al. (2020). Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523. https://doi.org/10.1038/s41467-020-13001-6.

162. McKay, P.F., Hu, K., Blakney, A.K., Samannu, K., Bouton, C.R., Rogers, P., Polra, K., Lin, P.J.C., Barbosa, C., Tam, Y., et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients. https://www.biorxiv.org/content/10.1101/2020.04.22.05608v1.

163. NCT04934111. Safety and immunogenicity of LNP-mCOV sRNA-02 vaccine against SARS-CoV-2, the causative agent of COVID-19 (COVAC-Uganda). https://www.clinicaltrials.gov/ct2/show/NCT04934111.

164. Arcturus Press Release. Arcturus therapeutics reports new data demonstrating neutralizing antibody immune response to the SARS-CoV-2 omicron variant from ARCT-154 and ARCT-165 booster clinical trial. https://ir.arcturusrx.com/news-release/news-release-details/arcturus-therapeutics-reports-new-data-demonstrating.

165. Elixirgen. Elixirgen therapeutics concludes Pre-IND meeting with FDA for its COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2: Preprint at bioRxiv. https://doi.org/10.1101/2021.11.08.467773.

166. Zephyr. COVID-19 update: Zephyr announces promising preclinical data.: ZIP-1642, Updated June 15, 2020, https://www.zephyr.bio/2020/06/15 ZIP-1642.

167. Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature 586, 516–527. https://doi.org/10.1038/s41586-020-2798-3.

168. Moderna White Paper. mRNA vaccines: disruptive innovation in vaccination. https://www.modernatx.com/sites/default/files/RNA_Vaccines_White_Paper_Moderna_050317_v8_4.pdf.

169. BioNTech Pfizer Press Release. Pfizer and BioNTech initiate study to evaluate omicron-based COVID-19 vaccine in adults 18 to 55 Years of age. https://investors. biontech.de/news-releases/news-release-details/pfizer-and-biontech-initiate-study-evaluate-omicron-based-covid.

170. Moderna. Moderna announces first participant dosed in phase 2 study of omicron-specific booster candidate: omicron booster study phase II, Updated January 31, 2022, https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participant-Dosed-In-Phase-2-Study-Of-Omicron-Specific-Booster-Candidate-and-Publication-of-Data-on-Booster-Durability-Against-Omicron-Variant/default.aspx.

171. Dolgin, E. (2021). How COVID unlocked the power of RNA vaccines. Nature 589, 189–191. https://doi.org/10.1038/d41586-021-00019-w.

172. Dolgin, E. (2021). mRNA flu shots move into trials. Nat. Rev. Drug Discov. 20, 801–803. https://doi.org/10.1038/s41573-021-00176-7.

173. Goldberg, M.S. (2019). Improving cancer immunotherapy through nanotechnology. Nat. Rev. Cancer 19, 587–602. https://doi.org/10.1038/s41568-019-0186-9.

174. Beck, J.D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, O., Vormehr, M., and Kranz, L.M. (2021). mRNA therapeutics in cancer immunotherapy. Mol. Cancer 20, 69. https://doi.org/10.1186/s12943-021-01348-0.

175. Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-L., and Huang, Y. (2020). The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534. https://doi.org/10.1016/j.biotechadv.2020.107534.

176. Vlatkovic, I. (2021). Non-Immunotherapy application of LNP-mRNA: maximizing efficacy and safety. Biomedicines 9. https://doi.org/10.3390/biomedicines9050530.

177. CDC Research. Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel. https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article.

178. Planas, D., Saunders, N., Maes, P., Guvel-Benhassine, F., Planchas, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021). Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature. https://doi.org/10.1038/s41586-021-04389-z.

179. Spitzer, A., Angel, Y., Marudi, O., Zeltser, D., Saiag, E., Goldshmidt, H., Goldiner, I., Stark, M., Halutz, O., Gamzu, R., et al. (2022). Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. https://doi.org/10.1001/jama.2021.23641.

180. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, O., Kranz, L.M., Berger, H., Petschien, J., et al. (2021). An inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 371, 145–153. https://doi.org/10.1126/science.abc9396.

181. Vormehr, M., Türeci, O., and Sahin, U. (2019). Harnessing tumor mutations for truly individualized cancer vaccines. Annu. Rev. Med. 70, 395–407. https://doi.org/10.1146/annurev-med-042617-101816.

182. CDC Research. Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel. https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article.

183. CDC Research. Effectiveness of mRNA BNT162b2 vaccine 6 months after vaccination among patients in large health maintenance organization, Israel. https://wwwnc.cdc.gov/eid/article/28/2/21-1834_article.

184. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, O., Kranz, L.M., Berger, H., Petschien, J., et al. (2021). An inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 371, 145–153. https://doi.org/10.1126/science.abc9396.

185. Krienke, C., Kolb, L., Diken, E., Streuber, M., Kirchhoff, S., Bukur, T., Akilli-Öztürk, O., Kranz, L.M., Berger, H., Petschien, J., et al. (2021). An inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 371, 145–153. https://doi.org/10.1126/science.abc9396.
synthetic KL4 peptide. J. Control Release 314, 102–115. https://doi.org/10.1016/j.jconrel.2019.10.026.

191. Abramson, A., Kirtane, A.R., Shi, Y., Zhong, G., Collins, J.E., Tamang, S., Ishida, K., Hayward, A., Wainer, J., Rajesh, N.U., et al. (2022). Oral mRNA delivery using capsule-mediated gastrointestinal tissue injections. Matter 87, 46. https://doi.org/10.1016/j.matt.2021.12.022.

192. Keikha, R., Hashemi-Shahri, S.M., and Jebali, A. (2021). The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanoparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta. Sci. Rep. 11, 21308. https://doi.org/10.1038/s41598-021-00830-5.

193. Kim, Y., Zheng, X., Eschke, K., Chaudhry, M.Z., Bertoglio, F., Tonjtic, A., Krmpotic, A., Hoffmann, M., Bar-On, Y., Boehme, J., et al. (2022). MCMV-based vaccine vectors expressing full-length viral proteins provide long-term humoral immune protection upon a single-shot vaccination. Cell. Mol. Immunol. https://doi.org/10.1038/s41423-021-00814-5.

194. Sun, Y., Zhang, X., Yang, S., Hu, C., Pan, J., Liu, T., Ding, J., Han, C., Huang, Y., and Yang, K. (2022). Preparation of antibodies against TXR1 and construction of a new DNA tumor vaccine. Int. Immunopharmacol 103, 108505. https://doi.org/10.1016/j.intimp.2021.108505.

195. Sakurai, F., Tachibana, M., and Mizuguchi, H. (2021). Adenovirus vector-based vaccine for infectious diseases. Drug Metab. Pharmacokinet. 42, 100432. https://doi.org/10.1016/j.dmpk.2021.100432.

196. Atasheva, S., Yao, J., and Shayakhmetov, D.M. (2019). Innate immunity to adenovirus: lessons from mice. FEBS Lett. 593, 3461–3483. https://doi.org/10.1002/1873-3468.13696.

197. Pfizer. Supporting manufacturing, trade and equitable global access to COVID-19 vaccines. https://cdn.pfizer.com/pfizercom/140122_PfizerFactsheet.pdf.

198. Moderna Website. Moderna’s mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. https://www.modernatx.com/responsibility/medicines-patients.